Program
Bortezomib
Also written as “bortezomib”, “VELCADE” and “VELCADE TM (bortezomib) for Injection”.
Its studies are mostly in Multiple Myeloma · Carcinoma, Non-Small-Cell Lung · Lymphoma, Mantle-Cell · Lymphoma, Follicular · Amyloidosis, led by 6 companies.
Drug pageBortezomib: every studyMany companies study it; this page follows only the 62 they lead. All 651 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Johnson & Johnson | 285 open or running | phase 4since Oct 15, 2014 | Sep 13, 2005 | Feb 14, 2029phase 3 · NCT04923893 |
| Takedaits history only | 250 open or running | phase 4since Nov 18, 2005 | Oct 28, 2002 | none ahead |
| Oncotherapeuticsits history only | 40 open or running | phase 2since Apr 24, 2006 | Apr 19, 2006 | none ahead |
| AbbVieits history only | 32 open or running | phase 3since Nov 28, 2023 | Aug 19, 2016 | Dec 2027phase 3 · NCT06158841 |
| AstraZenecaits history only | 10 open or running | phase 4since Aug 23, 2023 | Aug 23, 2023 | none ahead |
| Clinical Service, Chinaits history only | 10 open or running | phase 2since Mar 29, 2011 | Mar 29, 2011 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Johnson & Johnson only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 13 studies since Sep 13, 2005.
- Jan 27, 2011Phase 2 study in Multiple MyelomaNCT01286077 · 106 enrolled · Austria, Czech Republic, Denmark and more
- Nov 23, 2011Phase 3 study in Multiple MyelomaNCT01539083 · 256 enrolled · Australia, China, Korea, Republic of
- Feb 4, 20132 phase 3 studies in Multiple MyelomaNCT01910987, NCT01801436
- Jun 7, 2013Phase 2 study in Lymphoma, FollicularNCT01902862 · 7 enrolled · Germany
- Oct 15, 2014Phase 4 study in Multiple MyelomaNCT02268890 · 18 enrolled · Taiwan
- May 26, 2016Phase 3 study in Multiple MyelomaNCT02811978 · 81 enrolled · China
- Aug 1, 2016Phase 2 study in Multiple MyelomaNCT02874742 · 224 enrolled · United States
- Oct 31, 2016Phase 2 study in Multiple MyelomaNCT02951819 · 101 enrolled · United States
- Nov 27, 2019Phase 3 study in Multiple MyelomaNCT04181827 · 419 enrolled · United States, Australia, Belgium and more
- Jun 10, 2021Phase 3 study in Multiple MyelomaNCT04923893 · 743 enrolled · United States, Argentina, Australia and more
- Oct 8, 2021Phase 3 study in Multiple MyelomaNCT05083169 · 587 enrolled · United States, Argentina, Belgium and more
- Sep 30, 2022Phase 2 study in Lymphoma, Mantle-CellNCT05564052 · 36 enrolled · Brazil, Czechia, Greece and more
- Oct 5, 2022Phase 3 study in Multiple MyelomaNCT05572515 · 614 enrolled · United States, Australia, Austria and more
- Aug 27, 2024Phase 2 study in Multiple MyelomaNCT06577025 · 43 enrolled · United States, Australia, Brazil and more
Ahead
- Feb 14, 2029Primary completion: phase 3 study in Multiple MyelomaNCT04923893
- Sep 2, 2030Primary completion: phase 2 study in Multiple MyelomaNCT06577025
TargetBeta
“26S proteasome inhibitor; 26S proteasome inhibitor”ChEMBL 37, by rule
Other programs on the same 38 targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| carfilzomibrule | Amgen | phase 4 | 38 |
Studies
All 28 Johnson & Johnson leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06577025Multiple Myeloma · United States, Australia, Brazil and more | 2 | Active, not recruiting | Sep 2, 2030 | 43 |
| NCT05572515Multiple Myeloma · United States, Australia, Austria and more | 3 | Active, not recruiting | Oct 13, 2025 | 614 |
| NCT05564052Lymphoma, Mantle-Cell · Brazil, Czechia, Greece and more | 2 | Completed | Dec 6, 2023 | 36 |
| NCT05083169Multiple Myeloma · United States, Argentina, Belgium and more | 3 | Active, not recruiting | Aug 1, 2025 | 587 |
| NCT04923893Multiple Myeloma · United States, Argentina, Australia and more | 3 | Active, not recruiting | Feb 14, 2029 | 743 |
| NCT04181827Multiple Myeloma · United States, Australia, Belgium and more | 3 | Active, not recruiting | May 1, 2024 | 419 |
| NCT02951819Multiple Myeloma · United States | 2 | Completed | Mar 8, 2018 | 101 |
| NCT02874742Multiple Myeloma · United States | 2 | Completed | Jan 25, 2019 | 224 |
| NCT02811978Multiple Myeloma · China | 3 | Completed | May 7, 2018 | 81 |
| NCT02268890Multiple Myeloma · Taiwan | 4 | Completed | Jul 2015 | 18 |
| NCT01902862Lymphoma, Follicular · Germany | 2 | Terminated | Aug 2007 | 7 |
| NCT01801436Multiple Myeloma | 3 | Completed | Apr 2008 | 14 |
| NCT01910987Multiple Myeloma · Belgium, Finland, France and more | 3 | Completed | Feb 2016 | 80 |
| NCT01539083Multiple Myeloma · Australia, China, Korea, Republic of | 3 | Completed | Dec 30, 2015 | 256 |
| NCT01286077Multiple Myeloma · Austria, Czech Republic, Denmark and more | 2 | Completed | Nov 2012 | 106 |
| NCT00985959Multiple Myeloma · Japan | 1 | Completed | Jun 2010 | 101 |
| NCT00908232Multiple Myeloma · France, Germany, Greece and more | 2 | Completed | Aug 2011 | 163 |
| NCT00833560Multiple Myeloma · Germany | 2 | Completed | Jun 2009 | 401 |
| NCT00813150Multiple Myeloma · Germany | 3 | Completed | Jan 2013 | 96 |
| NCT00752518Multiple Myeloma | 2 | Completed | 35 | |
| NCT00718640Multiple Myeloma · Canada | 2 | Terminated | Dec 2009 | 10 |
| NCT00706953Multiple Myeloma | 2 | Withdrawn | Jun 2010 | 0 |
| NCT00561743Multiple Myeloma | 2 | Completed | May 2007 | 50 |
| NCT00441168Multiple Myeloma · Croatia, Germany, Hungary and more | 2 | Terminated | Jan 2008 | 30 |
| NCT00431769Multiple Myeloma · Austria, Belgium, France and more | 2 | Completed | Feb 2009 | 130 |
| NCT00416273Multiple Myeloma · Germany | 3 | Completed | May 2013 | 217 |
| NCT00416208Multiple Myeloma · Germany | 3 | Completed | May 2013 | 154 |
| NCT00216697Multiple Myeloma | 2 | Completed | 13 |
How it is read
Names in the registry
- “Bortezomib”, 42 entries
- “bortezomib”, 18 entries
- “VELCADE”, 6 entries
- “VELCADE TM (bortezomib) for Injection”, 2 entries
- “VELCADE TM (bortezomib) for Injection, or PS-341”, 2 entries
Conditions, from the studies’ own filings
- Multiple Myeloma, 61 studies
- Carcinoma, Non-Small-Cell Lung, 4 studies
- Lymphoma, Mantle-Cell, 3 studies
- Lymphoma, Follicular, 3 studies
- Amyloidosis, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.